Vertex inc - Search News

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Stockhouse · 4d

Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NDAQ:VRTX) Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

MarketWatch · 3d

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

The Motley Fool · 3d

Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?

The FDA is scheduled to make an approval decision for suzetrigine in treating acute pain by Jan. 30, 2025. This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years.

Yahoo Finance1d

Vertex, Inc. (VERX)

KING OF PRUSSIA, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on Built In ...

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

sharewise3d

Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

10d

Vertex Recognized in Built In’s Esteemed 2025 Best Places to Work Awards

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on ...

Vertex Pharmaceuticals: Strong Future Potential with Key Drug Launches and Underappreciated Opportunities

Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

Vertex Pharmaceuticals: Strong Pipeline and Strategic Growth Propel ‘Buy’ Rating

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results